These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 2974348)

  • 1. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
    Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB; Naruszewicz M
    Atherosclerosis; 1987 Feb; 63(2-3):203-9. PubMed ID: 3827981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A; Karádi I; Köszegi G; Pados G; Németh-Csóka M; Pichler M; Romics L
    Klin Wochenschr; 1990; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract]   [Full Text] [Related]  

  • 10. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP; Soltys G; Mangel R; Kwiterovitch P; Sniderman AD
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening and follow-up of infants with dyslipoproteinemia.
    Roseneu M; Van Biervliet JP
    Prog Clin Biol Res; 1985; 188():79-86. PubMed ID: 3933016
    [No Abstract]   [Full Text] [Related]  

  • 16. [Measurement of apolipoproteins is better than routinely measured traditional lipids].
    Kallner A; Estonius M
    Lakartidningen; 2006 Mar 8-14; 103(10):753-6, 758. PubMed ID: 16610202
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma exchange therapy in a patient with familial hypercholesteremia and generalized arteriosclerosis].
    Schrecker O; Thies K; Schlierf G
    Internist (Berl); 1984 Sep; 25(9):574-6. PubMed ID: 6386739
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term oil therapy and lipid metabolism in peripheral arterial obstructive disease].
    Reuter W; Voigt H; Herrmann W; Köhler H; Peters HJ; Kuklinski B; Lindhofer HG; Hanf S
    Z Gesamte Inn Med; 1985 Jun; 40(11):348-50. PubMed ID: 4036213
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute lipidemic effect of calcium heparin in normolipemic and hyperlipemic subjects.
    Ferlito S; Ricceri M; Ossino AM
    Int Angiol; 1989; 8(3):140-4. PubMed ID: 2592796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.